<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562272</url>
  </required_header>
  <id_info>
    <org_study_id>15849/20</org_study_id>
    <nct_id>NCT04562272</nct_id>
  </id_info>
  <brief_title>Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP</brief_title>
  <acronym>UNLOAD-AMI</acronym>
  <official_title>Attenuation of Post-infarct Remodeling in Patients With Acute Myocardial Infarction by Left Ventricular Mechanical Unloading Using Impella-CP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with anterior wall AMI treated by PCI will undergo, after successful&#xD;
      revascularization of the infarct artery, measurement of the left ventricular pressure, and&#xD;
      femoral angiogram. Patients with elevated LV pressure and adequate femoral access will be&#xD;
      randomized to standard pharmacological treatment of AMI vs. mechanical unloading by&#xD;
      Impella-CP (on top of the standard treatment) for 36-48 hours. LV unloading will be guided by&#xD;
      measurement of PCWP by Swan-Ganz catheter. On the day 4-7, and at 3 months after the AMI, the&#xD;
      patients will undergo SPECT and 3D-echocardiography to assess ventricular remodeling and&#xD;
      extent of the post-infarct scar. The patients will be followed for at least 12 months for the&#xD;
      occurrence of heart failure and adverse cardiovascular events. The study will test the&#xD;
      hypothesis, whether the LV mechanical unloading after PCI will attenuate post-infarct scar&#xD;
      and cardiac remodeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Eligible patients with be screened before PCI&#xD;
&#xD;
        2. The patients with undergo coronary angiography and PCI according to common medical&#xD;
           practice&#xD;
&#xD;
        3. At the end of the PCI procedure, after a successful revascularization, a pigtail&#xD;
           catheter will be used to measure LV filling pressure and to perform femoral angiography&#xD;
           (to evaluate femoral access).&#xD;
&#xD;
        4. Patients fulfilling angiographic and hemodynamic criteria will be randomized 1:1 to&#xD;
           standard care vs. mechanical unloading by Impella-CP.&#xD;
&#xD;
        5. The patients will be treated on a CCU with experience with use of Impella-CP.&#xD;
&#xD;
        6. On the CCU, all patients will be monitored by a Swan-Ganz catheter for 48 hours.&#xD;
&#xD;
        7. The pump speed will be adjusted to maintain the lowest tolerated PCWP while avoiding&#xD;
           suction events.&#xD;
&#xD;
        8. Mechanical unloading will last 36-48h. Afterwards, the Impella-CP will be explanted.&#xD;
&#xD;
        9. All patients will receive standard pharmacotherapy of AMI, according to the guidelines.&#xD;
&#xD;
       10. Revascularization of significant non-infarct lesions will be performed during the index&#xD;
           hospitalization.&#xD;
&#xD;
       11. 3D-echocardiography and Tc-SPECT (D-SPECT) will be performed on the day 5-7 of the index&#xD;
           hospitalization. LV phasic volumes and extent of nonperfused myocardium (scar) will be&#xD;
           evaluated automatically, using software provided by the vendor.&#xD;
&#xD;
       12. 3D-echocardiography and Tc-SPECT will be repeated at 3 months after the AMI.&#xD;
&#xD;
       13. The patients will be followed by out-patient check-ups every 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the left ventricular end-systolic volume</measure>
    <time_frame>LV end-systolic volume measured during the index hospitalization (day 5-7) and at 3 months</time_frame>
    <description>Absolute change in the LVESV measured by SPECT and compared between the groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of LV remodeling</measure>
    <time_frame>LV end-systolic volume measured during the index hospitalization (day 5-7) and at 3 months</time_frame>
    <description>Occurrence of LV remodeling defined by the increase of LV end-systolic volume &gt;20%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of post-infarct scar</measure>
    <time_frame>LV scar extent measured during the index hospitalization (day 5-7) and at 3 months</time_frame>
    <description>Extent of post-infarct scar measured by Tc-SPECT and compared between the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CV complications</measure>
    <time_frame>during the first 5 day after AMI</time_frame>
    <description>occurence of TIMI bleeding, hemolysis, thromboembolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart failure</measure>
    <time_frame>during the first 5 day after AMI</time_frame>
    <description>acute heart failure requiring inotropes or progression of cardiogenic shock</description>
  </secondary_outcome>
  <other_outcome>
    <measure>self-assessed dyspnea</measure>
    <time_frame>day 1, 2 and 5</time_frame>
    <description>dyspnea reported by the patient on a Likert scale</description>
  </other_outcome>
  <other_outcome>
    <measure>lung water</measure>
    <time_frame>day 1, 2 and 5</time_frame>
    <description>assessment of lung water score by ultrasound</description>
  </other_outcome>
  <other_outcome>
    <measure>maximum hs-TnT, BNP, serum lactate</measure>
    <time_frame>during the first 5 day after AMI</time_frame>
    <description>diference in hs-TnT, BNP and lactate between the groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Remodeling, Ventricular</condition>
  <condition>Shock, Cardiogenic</condition>
  <arm_group>
    <arm_group_label>Mechanical unloading</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment of AMI after PCI according to guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LV mechanical unloading by Impella-CP</intervention_name>
    <description>The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)</description>
    <arm_group_label>Mechanical unloading</arm_group_label>
    <other_name>Abiomed Impella-CP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  large anterior wall AMI with estimated ischemia of &lt;24h&#xD;
&#xD;
          -  at risk of the beginning of cardiogenic shock (SCAI A/B)&#xD;
&#xD;
          -  blood pressure &lt;160/100 mmHg&#xD;
&#xD;
          -  no previous IM based on the patient's history&#xD;
&#xD;
          -  no previously known LV systolic dysfunction&#xD;
&#xD;
          -  assumed new LV dysfunction documented by ECHO or LVG (LVEF &lt; 45%)&#xD;
&#xD;
          -  infarct culprit lesion at the proximal LAD, LMCA or equivalent, with TIMI &lt;= 2 flow&#xD;
&#xD;
          -  LV end-diastolic pressure of &gt;= 18 mmHg measured invasively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of chronic LV dysfunction&#xD;
&#xD;
          -  chronic anticoagulation therapy&#xD;
&#xD;
          -  the need of IIb/IIIa blockers at the PCI&#xD;
&#xD;
          -  inadequate femoral vein access (peripheral artery disease)&#xD;
&#xD;
          -  significant valve disease or valve prosthesis&#xD;
&#xD;
          -  CPR &gt;5 min before PCI&#xD;
&#xD;
          -  LV thrombus&#xD;
&#xD;
          -  periprocedural AMI (obliteration of large non-culprit artery during PCI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marek Sramko, MD, PhD</last_name>
    <phone>+420731682681</phone>
    <email>marek.sramko@ikem.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Sramko, MD, PhD</last_name>
      <phone>+420731682681</phone>
      <email>marek.sramko@ikem.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Marek Sramko</investigator_full_name>
    <investigator_title>Head of the Department of Acute Cardiology</investigator_title>
  </responsible_party>
  <keyword>ventricular assist device</keyword>
  <keyword>Impella</keyword>
  <keyword>unloading</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

